GVR Report cover Rat And Mouse Model Market Size, Share & Trends Report

Rat And Mouse Model Market Size, Share & Trends Analysis Report By Type (Knockout, Knock-in), By Technology, By Service (Breeding, Rederivation), By Application (COVID-19, CVS), By End-use, And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-4-68039-668-0
  • Number of Pages: 116
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2019
  • Industry: Healthcare

Report Overview

The global rat and mouse model market size was valued at USD 1.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.5% from 2021 to 2028. The growth of this market is majorly driven by the increasing demand for genetically modified models to help researchers identify and validate therapeutic targets. Additionally, increasing expenditures in R&D activities in the pharmaceutical and biotechnology sector is likely to fuel market growth. A rise in demand for humanized ACE2 (hACE2) mouse models to study the pathogenesis of SARS-CoV-2 propels the market growth. Several key players are focused to produce models that can aid in COVID-19 research. For instance, Applied StemCell, Inc.; a U.S.-based biotechnology company has used its TARGAT knockin technology to develop hACE2 models to assess the efficacy of vaccines, antiviral drugs, and evaluate the severity of COVID-19 pathogenesis.

China rat and mouse model market size, by service, 2018 - 2028 (USD Million)

The COVID-19 pandemic has created abundant opportunities for the market players. In September 2021, GemPharmatech Co., Ltd. (GPT) participated in the Biologics UK Oxford Global Conference to represent its humanized mouse models to assist the COVID-19 preclinical development.

The growth of personalized medicine boosts the demand for humanized rat and mouse models across the globe. Charles River Laboratories offers custom rare disease and microbiome models that support personalized therapy drug trials. The growing need for primary tissue/cells and human-like animal models propel the demand for customized models to assess safety, efficacy, and target validation in cellular therapies.

Type Insights

The outbred segment dominated the market for rat and mouse model and accounted for the largest revenue share of 22.6% in 2020. These models accurately represent the genomic structure of humans and hence are employed in research involving human subjects. Companies such as Charles River Laboratories have implemented global management programs to genetically link their outbred mouse and rat model under their International Genetic Standardization (IGS) program. This ensures that the company’s models across the globe are genetically alike.

Inbred strains accounted for the second-largest revenue share of the market owing to the advantages offered by them in disease research. These models are economical, readily available, homogenous, and are genetically stable. Additionally, they have a fully developed immune system and facilitate the analysis of novel drug candidates within the dynamics of a functional immune system. This makes inbred strains an ideal choice for the study of infectious diseases.

The knock-in segment is expected to witness the fastest CAGR in the market for rat and mouse model over the forecast period as they can be used to determine the effects of minute changes in the function and structure of proteins. This makes them well-suited for the determination of the functional significance of receptor-signaling pathways.

Technology Insights

Based on technology, the CRISPR/Cas9 technology segment dominated the market for rat and mouse model and accounted for the largest revenue share of 21.4% in 2020. CRISPR/Cas9 genome editing for the production of rat and mice models for human disease has transformed the field, with numerous advantages that include time savings, reduction in animal usage, and overall cost-effectiveness.

The use of CRISPR knock-in and knock-out rodent models in research involving human diseases has shown promising results. For instance, the application of CRISPR/CAS 9 to edit the β-globin gene has successfully enhanced the level of fetal hemoglobin for the treatment of sickle-cell diseases in mice.

Similarly, in September 2021, researchers from the Washington University School of Medicine used a mouse model to study the behavior of CRISPR engineered cells for the treatment of rheumatoid arthritis. The cells responded to inflammatory cytokines of mice and released anti-cytokine biologic drug in the model cells. Thus, companies such as Synthego, Cyagen, and others offer CRISPR edited mouse and rat models to capitalize on the growing opportunities offered by CRISPR technology.

Service Insights

Based on the services, the breeding segment dominated the market for rat and mouse model and accounted for the largest revenue share of 30.4% in 2020. This is attributed to the increasing demand for rat and mouse models for the development and drug discovery and subsequent increase in the demand for personalized medicines. Companies such as Taconic Biosciences, Inc.; Cyagen; and others offer CRISPR edited mouse and rat models to capitalize on the growing opportunities offered by CRISPR technology.

The cryopreservation segment is expected to witness the fastest CAGR throughout the forecast period. Cryopreservation of embryo and sperm from rat and mouse models creates a cost-efficient backup of live animal colonies which do not have many applications in the present scenario but may prove to be extremely useful in the future.

Cryoservices offered by key companies, such as Charles River Laboratories, help in the protection of animal lines in case of natural disaster, a catastrophic accident, microbial contamination, and alteration of gene expression in later generations. The service also prevents loss of phenotype, limits genetic drift, and ensures easy recovery of VAF/Elite rats and mice.

Application Insights

The cancer segment dominated the market for rat and mouse model and accounted for the largest revenue share of 17.9% in 2020. Rat and mice models provide various aspects of progression, genesis, and clinical course of human cancers. Therefore, they act as significant models for cancer researchers involved in basic, clinical, translational, and epidemiological studies.

With the successful development and implementation of mRNA vaccines for COVID-19, their makers are now exploring ways to use mRNA therapies for other diseases including cancer. In September 2021, a team of researchers from BioNTech; COVID-19 vaccine partner of Pfizer; used mouse models to study the effects of mRNA cocktails that produce cancer-fighting molecules. This resulted in the successful suppression of malignant tumors in mouse models of melanoma and colon cancer.

Therefore, a rise in initiatives to utilize rodent models for cancer drug development is expected to increase the revenue generation in this segment. Moreover, the mouse genome is extremely homologous to the human genome to simulate biological characteristics such as the occurrence, development, and metastasis of human cancer cells in vivo for convenient feeding, low price, and easy gene modification.

End-use Insights

The pharmaceutical and biotechnology companies segment held the largest revenue share of 41.9% in 2020. Increasing applications of the rat and mice model in the production of vaccines for infectious diseases are expected to boost the segment further during the forecast period. Mice are commonly used as model organisms to test vaccine candidates as they have a defined genome, a well-characterized immune system, and can reproduce at a rapid rate.

The development of mouse models that can generate a human version of ACE2 has increased their adoption rate in the pharmaceutical and biotechnology companies for COVID-19 research. Moreover, the rise in collaboration between biotechnology companies and academic institutions to produce COVID-19 vaccines boosts revenue generation in the market.

Global rat and mouse model market share, by end-use, 2020 (%)

For instance, in September 2021, researchers from Sementis Ltd; a biotechnology company in Adelaide; and the University of South Australia collaborated for COVID-19 vaccine development. The team employed mouse models to develop a vaccine that encodes SARS-CoV-2 spike glycoprotein. The vaccinated mice showed rapid development of robust spike-specific CD8 T cells which generated a substantial immune response against the viral infection.

Regional Insights

North America dominated the rat and mouse model market and accounted for the highest revenue share of 49.8% in 2020. This is attributed to the presence of key market players and the growth in pharmaceutical as well as research sectors in this region. According to a January 2021 research publication, rat and mouse models comprise 99.3% of the mammals used in 16 large American institutions. Therefore, a high utilization rate of these models in the region propels revenue growth.

Europe held the second-largest market share owing to the rise in research activities involving the use of rodent models. In September 2021, a team of researchers from the Universitat Autònoma de Barcelona (UAB); Spain generated a rat model which could recapitulate the disabling alterations observed in patients with Morquio A disease or Mucopolysaccharidosis type IVA.

The researchers have also successfully tested gene therapy which cures alterations of the whole body observed in rat models with Morquio A disease. Such types of research activities can potentially lead to the discovery of novel therapies which could treat young patients with life-threatening alterations. This also encourages drug developers to use rodent models for drug discovery and development.

Key Companies & Market Share Insights

The market is flooded with the presence of many small, medium, and large providers of rat and mouse models as well as testing services. A significant number of businesses hold a major share in their respective regions. Taconic Biosciences, Inc. is one of the key players who provide a wide range of innovative solutions. The company’s models are used by researchers and professionals globally.

Similarly, Charles River Laboratories has more than 20 breeding facilities across the globe for the generation of rat and mice animal models. Key players have also adopted growth strategies to expand their market share. For instance, in February 2020, Taconic Biosciences began the production of mouse models with the humanized immune system in Europe. This expanded the company’s manufacturing capacity as well as its customer base in Europe. Some of the prominent players in the rat and mouse model market include:

  • Charles River Laboratories International, Inc.

  • The Jackson Laboratory

  • Laboratory Corporation of America Holdings (Covance)

  • Perkin Elmer (Horizon Discovery Group plc)

  • genOway

  • Envigo


  • Taconic Biosciences, Inc.

  • Biomedical Research Models (Biomere)

  • Transpogen Biopharmaceutical, Inc.

Rat And Mouse Model Market Report Scope

Report Attribute


Market size value in 2021

USD 2.03 billion

Revenue forecast in 2028

USD 2.93 billion

Growth Rate

CAGR of 5.5% from 2021 to 2028

Base year for estimation


Historical data

2018 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segment coverage

Type, technology, service, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; France; U.K.; Italy; Spain; Japan; China; India; Brazil; Mexico; South Africa; Saudi Arabia

Companies profiled

Charles River Laboratories International, Inc.; The Jackson Laboratory; Laboratory Corporation of America Holdings (Covance); Perkin Elmer (Horizon Discovery Group plc); genOway; Envigo; JANVIER LABS; Taconic Biosciences Inc.; Biomedical Research Models (Biomere); Transpogen Biopharmaceutical, Inc.

Customization scope

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global rat and mouse model market report based on type, technology, service, application, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2018 - 2028)

    • Knockout

    • Knock-in

    • Outbred

    • Inbred

    • Others

  • Technology Outlook (Revenue, USD Million, 2018 - 2028)

    • Nuclear transferase

    • Microinjection

    • Embryonic stem cells

    • CRISPR/Cas9

    • Others 

  • Service Outlook (Revenue, USD Million, 2018 - 2028)

    • Cryopreservation

    • Breeding

    • Rederivation

    • Genetic testing

    • Quarantine depending

    • Others

  • Application Outlook (Revenue, USD Million, 2018 - 2028)

    • Cardiovascular diseases

    • Genetic diseases

    • Cancer

    • Infectious diseases

      • COVID-19

      • Others

    • Transplantation

    • Toxicology studies

    • Others 

  • End-use Outlook (Revenue, USD Million, 2018 - 2028)

    • Pharmaceutical companies

    • Academic and research facilities

    • Biotechnology companies

    • Contract research & manufacturing organizations

  • Regional Outlook (Revenue, USD Million, 2018 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

      • U.K.

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

ESOMAR Certified Member Great Place to Work Certified

ESOMAR & Great Work to Place Certified

ISO 9001:2015 & 27001:2022 Certified

ISO 9001:2015 & 27001:2022 Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.